David Ridley PhD

David Ridley is the Faculty Director for Health Sector Management at Duke University’s Fuqua School of Business. He studies pharmaceutical innovation, manufacturing, and prices. He is especially interested in how to encourage development of drugs and vaccines for neglected diseases. David was the lead author of the paper proposing the priority review voucher program which became law and created a market of more than a billion dollars for drug development for neglected diseases. His research has been funded by the Bill & Melinda Gates Foundation and the National Institutes of Health. David teaches courses on health care policy and strategy to Duke University graduate students. He received a doctorate in economics from Duke University.

Ridley DB, Lasanta AM, Storer Jones F, Ridley SK. European priority review vouchers for neglected disease product development. BMJ global health. 2024 Jan;9(1):e013686.

Liebman E, Lawler EC, Dunn A, Ridley DB. Consequences of a shortage and rationing: Evidence from a pediatric vaccine. Journal of health economics. 2023 Dec;92:102819.

Cuddy E, Lu YP, Ridley DB. FDA Global Drug Inspections: Surveillance Of Manufacturing Establishments Remains Well Below Pre-COVID-19 Levels. Health affairs (Project Hope). 2023 Dec;42(12):1758–66.